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Systemic administration of the immunosuppressive drug cyclosporin A (CsA) is frequently associated with a 
number of side effects; therefore, sometimes it cannot be applied in sufficient dosage after allogeneic or xeno-
geneic cell transplantation. Local delivery is a possible solution to this problem. We used 3D printing to develop 
a CsA-loaded 3D drug carrier for the purpose of local and sustained delivery of CsA. The carrier is a hybrid of 
CsA-poly(lactic-co-glycolic acid) (PLGA) microsphere-loaded hydrogel and a polymeric framework so that 
external force can be endured under physiological conditions. The expression of cytokines, which are secreted 
by spleen cells activated by Con A, and which are related to immune rejection, was significantly decreased in 
vitro by the released CsA from the drug carrier. Drug carriers seeded with xenogeneic cells (human lung fibro-
blast) were subcutaneously implanted into the BALB/c mouse. As a result, T-cell-mediated rejection was also 
significantly suppressed for 4 weeks. These results show that the developed 3D drug carrier can be used as an 
effective xenogeneic cell delivery system with controllable immunosuppressive drugs for cell-based therapy.
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INTRODUCTION
Cell-based therapy (CBT) has been developed as a prom-
ising approach for treatment of diseases such as muscular 
dystrophy, degenerative disc disease, or myocardial infarc-
tion (11,12,45). However, CBT requires use of allogeneic 
or xenogeneic cells, which stimulate an immune rejection 
response (11,12,45,48,50), so immunosuppressive drugs 
must be administered to prevent acute transplant rejection 
after cell transplantations (9,26). Calcineurin inhibitors 
such as cyclosporin A (CsA) or tacrolimus (FK506) are 
the most widely used immunosuppressive drugs (6,20,43). 
They deactivate a nuclear factor of activated T-cell (NFATc) 
protein so that immune rejection-related cytokines like 
interleukin-2 (IL-2), IL-17, and interferon-g (IFN-g) cannot 
be encoded in the early phase of T-cell activation (28). The 
introduction of CsA improves the success rate of various 
transplantations (3,14,25), but systemic administration of 
CsA requires a high dose of drug, which causes severe side 
effects such as nephrotoxicity, hypertension, dyslipidemia, 
gingivitis, and hirsutism (19). To avoid these problems, 
local CsA delivery of a relevant dose of drugs can be a 
promising solution.
Many trials have attempted CsA delivery using deliv-
ery systems based on microspheres or hydrogels, but most 
reports were limited to systemic delivery of CsA (44) and 
mostly considered ophthalmic (17,46) or dermatological 
(21) applications. These delivery systems have some crit-
ical problems. Microsphere-based drug delivery systems 
can cause embolisms or further organ damage due to emi-
gration of the microspheres from the injection site (37). 
Furthermore, microspheres are susceptible to phagocy-
tosis by macrophages (34). Hydrogel-based delivery 
systems can result in relatively rapid drug release over 
intervals of a few hours to a few days; this speed may 
be undesirable. Moreover, the weak mechanical proper-
ties of hydrogel preclude its application to sites that have 
highly demanding load-bearing capacity. Low mechani-
cal properties usually cause premature dissolution during 
material injection. Moreover, the intermolecular disper-
sion phenomenon inhibits releasing the encapsulated 
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drugs, which are located within the hydrophilic releasing 
system. (8,18).
Several studies have considered local (19,32) or sus-
tained (33) delivery of CsA, but none have considered 
local and sustained release simultaneously to prevent 
immune rejection of transplanted tissues. The objectives of 
this study are to show the feasibility of using a subcutane-
ous 3D-printed drug delivery system to achieve local and 
sustained release and investigate local immunosuppressive 
effects of CsA after xenogeneic cell transplantation.
MATERIALS AND METHODS
Animals
Seven- to 10-week-old C57BL/6 male mice and 
6-week-old BALB/c male mice were purchased from 
Orient Bio (Seoul, Korea). All animal protocols were 
approved by Institutional Animal Care and Use Committee 
of POSTECH.
Materials
Cyclosporin A (CsA) (BML-A195-0500, MW 1202.6, 
purity ³ 98%) was purchased from Enzo Biochem (New 
York, NY, USA). Poly(lactic-co-glycolic acid) (PLGA) 
(430471-5G, MW 50,000–75,000), alginic acid sodium 
salt (alginate; A0682-100G, low viscosity), concanava-
lin A (ConA) (L7647-100MG), HEPES buffer, eosin, 
and poly(vinyl alcohol) (PVA) (363073-500G, MW 
31,000–50,000) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Polycaprolactone (PCL) (19561-500G, 
MW 43,000–50,000) was purchased from Polysciences 
(Warrington, PA). Hematoxylin was purchased from 
Dako (Carpinteria, CA, USA). RPMI-1640 and DMEM 
high-glucose were purchased from Hyclone (Logan, UT, 
USA). Fetal bovine serum (FBS) and antibiotics (peni-
cillin–streptomycin) were purchased from Gibco (Grand 
Island, NY, USA). 2-Mercaptoethanol was purchased from 
Biosesang (Seongnam, Korea). Optimal cutting tempera-
ture (OCT) compound was purchased from Tissue-Tek 
(Miles Laboratories, Elkhart, IN, USA). Dichloromethane 
(DCM) [M0821, assay (GC) ³ 98%] was purchased from 
Samchun Chemicals (Seoul, Korea). Calcium chloride 
(CaCl2) (07057-00) was purchased from Kanto Chemical 
(Tokyo, Japan). Tween 80 (T1004) was purchased from 
USB (Cleveland, OH, USA).
Fabrication of CsA-Loaded 3D Drug Carriers
Preparation of the Mixture of CsA-Loaded PLGA 
Microspheres and Alginate Hydrogel. A hydrogel-based 
drug delivery system is usually restricted to burst release, 
and a hydrophobic drug cannot be easily loaded directly 
into the hydrophilic carrier. To encapsulate hydrophobic 
drugs into the hydrogel stably and homogeneously, we pre-
pared hydrophobic drug-loaded polymeric microspheres 
(Fig. 1). The mixture of drug-loaded microsphere and 
hydrogel enables sustained drug release (22,42). In this 
study, CsA, which is hydrophobic, was loaded into PLGA 
microspheres, which were mixed with alginate hydrogel.
The CsA-loaded PLGA microspheres were prepared 
using the oil-in-water solvent evaporation technique (7) 
(Fig. 1a). Briefly, an organic phase was prepared by dis-
solving 120 mg of PLGA and 12 mg of CsA in 0.9 ml 
of DCM. An aqueous phase was prepared by dissolv-
ing 180 mg of PVA in 18 ml of deionized (DI) water. A 
mixture of the organic and aqueous phase was emulsi-
fied using a sonicator (Sonic Dismembrator Model 100; 
Fisher Scientific, Indiana, PA, USA) for fabricating 
microspheres (Fig. 1b). The emulsion was formed by 
sonication at 6-W output power for 90 s. The prepared 
emulsion was mixed with 50 ml of 0.1 wt% PVA solution 
and gently stirred for >4 h to evaporate organic solvents. 
Then the emulsions were centrifuged and washed three 
times to remove remaining organic solvents. The micro-
spheres were deep frozen at −70°C and dried in a −90°C 
freeze dryer (Operon, Gimpo, Korea) for 1 day and stored 
at −20°C. Finally, the prepared CsA-loaded microspheres 
were loaded into the 8 wt% alginate hydrogel.
Fabrication of CsA-Loaded 3D Drug Carriers. We used 
our lab-built biomedical 3D printer (38,41) to fabricate a 
CsA-loaded 3D drug carrier, which is composed of two com-
ponents: 8 wt% alginate hydrogel loaded with CsA-PLGA 
microspheres (CsA-Algi gel) and a blended PCL/PLGA 
synthetic polymer (PCL/PLGA structure) for improving the 
load-bearing capacity of the whole structure.
PCL and PLGA were mixed thoroughly at a 1:1 ratio 
(w/w) at 160°C. The blended PCL/PLGA was loaded in 
a syringe and melted at 125°C, then dispensed at 500 kPa 
using a pneumatic pressure-regulated dispenser to print 
three pairs of parallel lines of the PCL/PLGA structure, with 
pairs joined at alternating ends (Fig. 1c). CsA-Algi gel was 
dispensed between the lines in each pair using a plunger-
based low-dosage dispensing system (Fig. 1d). The printing 
and dispensing processes were repeated three times to form 
a layered structure with the lines in each layer oriented right 
at angles to those in the layer below it (Fig. 1e).
Characterization of CsA-Loaded PLGA Microspheres
Size Distribution of CsA-Loaded PLGA Microspheres. 
The size (Z-Ave) of the CsA-loaded PLGA micro-
spheres was measured by using dynamic light scattering 
(Zetasizer, Malvern, UK). The CsA-loaded PLGA micro-
spheres were suspended in an aqueous solution and mixed 
using a vortexer (Fisher Scientific) before analysis.
Evaluation of Drug Content and Encapsulation 
Efficiency. The amount of CsA encapsulated in PLGA 
microspheres was quantified by high-performance liq-
uid chromatography (HPLC) (Waters Alliance 2695). 
CsA-loaded microspheres were dissolved in acetonitrile 
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(Burdick & Jackson, Muskegon, MI, USA) and ade-
quately diluted before injection into the HPLC system. 
Separation was achieved on an XBridge C18 column 
(4.6 × 250 mm) (Waters, Milford, MA, USA). The elution 
was isocratic at 1.0 ml/min with a mobile phase that con-
sisted of a 4:1 (v/v) mixture of acetonitrile and distilled 
water. The injection volume was 50 μl, and detection was 
monitored for absorbance at 210 nm.
The CsA drug content was calculated as
 
= ×CsA content (%) 100%CsA
MS
W
W
 (1)
where WCsA represents the weight of quantified CsA, and 
WMS represents the weight of CsA-loaded microspheres.
The encapsulation efficiency was calculated as
= ×CsA encapsulation efficiency (%) 100%sphere
total
CsA
CsA
 (2)
where CsA
sphere represents the weight of quantified CsA, 
and CsA
total represents the weight of CsA initially added.
Morphological Characterization of CsA-Loaded PLGA 
Microspheres and 3D Drug Carriers
The morphological analysis of the CsA-loaded micro-
spheres and 3D drug carrier was performed using a scan-
ning electron microscope (SEM) (Hitachi SU-6600, 
Tokyo, Japan) at an accelerating voltage of 15 kV. Before 
SEM imaging, samples were deep frozen at −70°C, dried 
in a −90°C freeze dryer for 1 day, and coated with plati-
num (Hitachi).
In Vitro Release Profile Test
A cumulative release profile of CsA from CsA-Algi 
gel was measured using a dialysis method. A total of 
10.868 μg of CsA was loaded into PLGA microspheres, 
which were then mixed with alginate solution at a con-
centration of 10 wt%, then cross-linked using CaCl2 
(Junsei, Tokyo, Japan)
.
The prepared gel was put inside a cellulose dialy-
sis bag (MW cutoff 3500; Thermo Fischer Scientific, 
Rockford, IL, USA) with 3 ml of 0.1 M phosphate buffer 
(pH 7.4) containing 0.01% (w/v) Tween 80. This method 
avoids the loss of microspheres during the experiment. 
The dialysis bag with the gel was suspended in the phos-
phate buffer (16), then incubated at 37°C. At predeter-
mined intervals, 1 ml of suspension was collected, and 
the same amount of fresh medium was added. The drug 
release was quantified using HPLC.
Cell Culture
Spleen cells were isolated from C57BL/6 male mice 
at the age of 7–10 weeks and cultivated in a RPMI-1640 
medium supplemented with 10% FBS, 1% antibiotics 
(penicillin–streptomycin), 10 mM HEPES buffer, and 
5 × 10−5 M 2-mercaptoethanol (referred to as a spleen 
cell culture medium). The cells (1 × 106 cells/well) were 
cultured in 200 μl of culture medium in 96-well tissue 
culture plates (Corning, Corning, NY, USA) stimulated 
with 2 μg/ml of ConA for 3 days (referred to as ConA-
activated spleen cells). A human lung fibroblast (HLF, 
sex unknown) cell line was purchased from Lonza (Basel, 
Switzerland) and cultured in a DMEM high-glucose 
medium supplemented with 10% FBS and 1% antibiot-
ics (referred to as a HLF culture medium). All the cells 
were incubated at 37°C in 100-mm tissue culture plates 
(BD Biosciences, San Jose, CA, USA), in 5% CO2 and 
95% air.
Cycotoxicity Test of the Fabricated CsA-Loaded 
3D Drug Carriers
To verify the cytotoxicity of CsA-loaded 3D drug carri-
ers, HLFs were seeded onto the CsA-loaded 3D drug carrier 
at a concentration of 5 × 104 cells/drug carrier and cultured 
for 7 days. A cell counting kit (Cell Counting Kit-8; Dojindo, 
Kumamoto, Japan) was used to evaluate cell numbers at 
days 1, 4, and 7.
Enzyme-Linked Immunosorbent Assay for Investigating 
CsA-Loaded 3D Drug Carriers
ConA-activated spleen cells were used to assess the 
CsA-loaded 3D drug carriers in vitro. The cells were 
loaded in a 96-well plate at a concentration of 1 × 106 
cells/well and used for all the following assessments
First, a CsA dose-screening test was conducted to find 
the appropriate concentration of the drug. Concentrations 
of 1, 10, 100, and 200 μg/ml were selected based on sev-
eral reports (4,19,27) and applied to the cell-seeded well 
plate. The cells were cultured for 24 h, and the cells with 
cell culture media were harvested for further assay.
The immunosuppressive effect of CsA-loaded 3D 
drug carriers was investigated. In this study, 200 μg/ml of 
CsA was selected as representative concentration of 3D 
drug carriers according to the drug dose screening test. 
3D drug carriers without CsA were used as a negative 
control, and ConA-activated spleen cells without CsA 
treatment was used as a positive control. All the groups 
were cultured for 24 h and harvested.
The secreted cytokines were quantified using enzyme-
linked immunosorbent assay (ELISA) using the superna-
tant of harvested samples. IL-2, IL-17, and IFN-g were 
selected as representative immunomodulatory cytokines, 
and ELISA was conducted following the manufacturer’s 
instructions (BioLegend, San Diego, CA, USA).
In Vivo Assessments of CsA-Loaded 3D Drug Carriers
To investigate the immunosuppressive function, we 
implanted CsA-loaded 3D drug carriers with HLF into the 
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dorsal subcutaneous space of each of five male BALB/c 
mice. HLFs were seeded onto the CsA-loaded 3D drug 
carriers [(+)HLF (+)CsA] at 5 × 104 cells/carrier, and the 
cell-seeded 3D drug carrier without CsA, [(+)HLF (−)
CsA] and the 3D drug carrier without CsA [control, (−)
HLF (−)CsA] were used as controls. (+)HLF (+)CsA and 
(+)HLF (−)CsA groups were stabilized for 24 h before 
implantation. Animal experiments were performed 
according to the protocol approved by the Animal Care 
and Use Committee of the Pohang University of Science 
and Technology, South Korea (2013-0030). The mice 
were sacrificed, and all 3D drug carriers were retrieved 
1, 3, or 4 weeks after implantation and fixed in formalin 
(Daejung, Gyeonggi, Korea). Samples were embedded 
in paraffin (two samples/group) and in OCT compound 
(three samples/group) for histological analysis. Paraffin-
embedded samples were sectioned transversely using a 
microtome for hematoxylin and eosin (H&E) staining. 
Samples embedded in OCT compound were sliced using 
a cryotome (Leica, Bensheim, Germany) for immuno-
fluorescence staining. All sections were 5 μm thick.
Infiltration of mononuclear cells such as macrophages 
and lymphocytes is an important indicator of transplant rejec-
tion. Therefore, tissue sections were stained with H&E to 
evaluate the infiltration of mononuclear cells by xenogeneic 
cell transplants. At least three SEM images were randomly 
selected for each group, and the number of mononuclear 
cell infiltrations was counted manually. Immune rejection 
responses were evaluated by immunofluorescence staining of 
the CD4+ and CD8+ T cells. CD4+ antibodies (1:30, a-CD4-
biotin; Life Technologies, Paisley, UK) were applied for 15 
min, then secondary antibody (1:100, streptavidin-Alexa 
594; Molecular Probes, Eugene, OR, USA) was applied for 
2 h. CD8+ antibody (1:200, Alexa488-conjugated-a-CD8a; 
Life Technologies) was applied for 15 min.
All slides were mounted with DAPI (GBI Labs, 
Mukilteo, WA, USA) solution and were examined under a 
light microscope (Nikon Eclipse E600; Nikon Instruments, 
Melville, NY, USA) and confocal laser microscope 
(Olympus, Tokyo, Japan).
Statistical Analysis
All data are expressed as mean ± standard deviation. 
All statistical analyses were performed using SigmaPlot 
software (ver. 10.0; Systat Software Inc., San Jose, CA, 
USA). Statistical significance was determined using two-
tailed Student’s t-test and one-way analysis of variance 
(ANOVA), followed by Tukey’s test. Differences were 
considered to be statistically significant at p < 0.05.
RESULTS
Characterization of CsA-Loaded 3D Drug Carriers
Characterization of CsA-Loaded PLGA Microspheres. 
The CsA content of prepared microspheres was 8.65%, and 
the measured CsA encapsulation efficiency was ~50%.
The surface morphology of microspheres was exam-
ined by analysis of SEM images (Fig. 2a). CsA-loaded 
PLGA microspheres showed rougher surfaces than PLGA 
microspheres without CsA. The measured average diam-
eter of microspheres was 1.843 μm, and the data (Fig. 2b) 
were normally distributed.
Morphological Analysis of 3D Drug Carriers. The 
fabricated 3D drug carrier was 4.2 × 4.2 × 1.8 mm with a 
pore size of 600 μm and a line width of 200 μm.
We printed the hydrogel selectively in between the 
lines of the 3D drug carrier so that the carrier maintains 
pore interconnectivity. The hydrogel was successfully 
dispensed in alternate spaces between alternate pairs of 
parallel lines of the PCL/PLGA structure (Fig. 3).
Cell Cytotoxicity of CsA-Loaded 3D Drug Carriers. 
The CsA-loaded 3D drug carriers (DC-CsA) caused no 
cytotoxicity. The CsA-loaded 3D drug carrier group 
showed similar initial cell attachment to the 3D drug car-
rier without CsA (DC) group, and all groups had similar 
proliferation rates for 7 days (Fig. 4).
Figure 2. Analysis of the prepared CsA-loaded PLGA microspheres. (a) SEM analysis of the prepared CsA-loaded PLGA 
 microspheres. (b) Intensity particle size distributions of CsA-loaded PLGA microspheres (Zetasizer, mean diameter: 1.843 μm).
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In Vitro Drug Release Profile Test
A cumulative release profile of CsA from the CsA-
Algi gel showed an initial burst release followed by a 
sustained release of CsA (Fig. 5) (1). After burst release 
on day 1, CsA-Algi gel released drugs sustainedly for 4 
weeks, and almost 75% of CsA was released from the 
CsA-Algi gel by day 28.
Determination of Effective Drug Concentration
Cytokine expression decreased significantly as CsA 
concentration increased, and the 200 μg/ml dosage sup-
pressed IL-2, IL-17, and IFN-g secretion effectively 
(Fig. 6). Based on these results, 200 μg/ml CsA was 
determined as an effective concentration and was used 
when fabricating the CsA-loaded 3D drug carrier.
Evaluation of Immunomodulatory Effect of  
CsA-Loaded 3D Drug Carriers
Immunomodulatory Effect of CsA-Loaded 3D Drug 
Carriers In Vitro. The DC-CsA group significantly inhib-
ited secretion of IL-2, IL-17, and IFN-g cytokines; the 
DC group did not (Fig. 7).
Immunomodulatory Effect of CsA-Loaded 3D Drug 
Carriers In Vivo. In this experiment, we seeded HLFs on the 
fabricated 3D drug carriers and subcutaneously implanted 
them into a BALB/c mouse to confirm their immuno 
modulatory effects, as well as their prospects as xenoge-
neic cell carriers (Fig. 8a). Infiltration by mononuclear cells 
was observed by H&E staining. To verify T-cell-mediated 
rejection, numbers of CD4+ and CD8+ T cells were quanti-
fied using immunofluorescence staining. Overall, the level 
of the mononuclear cell infiltration decreased over time in 
all groups and was highest in the (+)HLF (−)CsA group 
for the entire month (Fig. 8b, c). After 1 week, the level of 
mononuclear cell infiltration of (+)HLF (+)CsA group was 
slightly higher than that of the control group, but the num-
ber of cells eventually decreased with time and was similar 
to that of the control group after 3 and 4 weeks. To verify 
the immune rejection phenomena of xenogeneic cells, 
we conducted immunofluorescence staining of the CD4+ 
and CD8+ T cells, which mainly indicate helper T cells 
and cytotoxic T cells, respectively. The overall transplant 
rejection response decreased from 1 to 4 weeks. T-cell-
mediated immune response did not appear in the control 
Figure 3. SEM images of 3D drug carrier. (a) 3D drug carrier without CsA (PCL/PLGA + 8 wt% alginate hydrogel), (b) CsA-loaded 
3D drug carrier (PCL/PLGA + 8 wt% alginate hydrogel + CsA-loaded PLGA microsphere).
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group, whereas CD4+ and CD8+ T cells were significantly 
more numerous in the (+)HLF (−)CsA group than in the 
(+)HLF (+)CsA group during all 4 weeks (Fig. 9). All the 
implanted structures were maintained for 4 weeks without 
any disruption phenomenon (Fig. 10).
DISCUSSION
Immunosuppressive drugs must be administered after 
allogeneic or xenogeneic cell transplantation to prevent 
recipients’ immune systems from rejecting the transplant. 
However, systemic administration of immunosuppres-
sive drugs is usually associated with severe side effects. 
The developed CsA-loaded 3D drug carrier enables sus-
tained release of CsA at a desired site and can therefore be 
emplaced near the transplanted tissue to deliver the drug 
only where it is needed, thereby avoiding the side effects. 
The drug carrier shows stable drug release kinetics over 
4 weeks. This result indicates that a mechanically robust 
3D drug carrier has great advantages for solving a number 
of problems, which have frequently occurred in hydrogel-
based drug delivery systems. One of the main advantages 
of the developed drug carrier is the structural integrity of 
the drug-loaded hydrogel, which is a very important fac-
tor for the quantity and homogeneity of drug release (18) 
and for maintaining the optimal therapeutic drug levels by 
sustained drug release (13). In addition, we expected that 
the developed drug carrier has tailored properties to control 
the drug release behavior by modifying several parameters 
such as the size of the microspheres (5), the concentration 
of the hydrogel (51), and the ratio of lactide and glycolide 
of PLGA (51). The CsA-Algi gel can also be utilized as a 
carrier for cell transplantation. The CsA-loaded 3D drug 
carrier, which is composed of the CsA-Algi gel and the 
PCL/PLGA polymeric framework, can endure a compres-
sive force up to several 10s of MPa (23,31,36,39,40,47), 
and can thus resist breaking and unintentional fast drug 
release. Many researchers have investigated the improve-
ment of the mechanical properties of hydrogels. One of 
the best-known methods is an interpenetrating polymer 
network (IPN) system, which has garnered significant 
Figure 5. HPLC-based in vitro cumulative release profiles of CsA at 37°C from CsA-Algi gel as a function of time.
Figure 4. CCK assay for the attachment and proliferation of 
HLF on fabricated 3D drug carriers with and without CsA (DC, 
3D drug carriers without CsA; DC-CsA, CsA-loaded 3D drug 
carriers). *p < 0.05, **p < 0.005.
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attention in the last two decades (30). Of all those systems, 
IPN-based double-network (DN) hydrogels have extremely 
high compressive fracture strength of around 17.2 MPa 
(15). In this respect, we have confirmed that the developed 
drug carrier has comparable mechanical stability with pre-
viously developed DN hydrogels (39). This mechanically 
stable structure might facilitate application to the high 
load-bearing tissue site for cell-based therapeutics, most 
representatively in orthopedics such as the regeneration of 
bone defects (24), the repair of joint surface damage (35), 
or the treatment of osteoarthritis (29).
The developed CsA-loaded 3D drug carriers are non-
cytotoxic and show immunomodulatory effects in vitro. 
Adequate amounts of CsA were released from the carrier so 
that the released drug prohibited acceleration of secretion of 
cytokines (e.g., IL-2, IL-17, and IFN-g) related to immune 
rejection. Th1 cytokines like IL-2 and IFN-g secreted by 
Th1 cells are known to accelerate the cell-mediated immune 
response during the immune rejection process. Th17 cells 
selectively produce IL-17 cytokine and contribute to the 
acute rejection of xenotransplants (2,10,49). Consequently, 
the developed carrier can be applied to reduce acute trans-
plant rejection by inhibition of cytokines from Th1 and 
Th17 cells, which are crucial factors of acute rejection in 
the xenogeneic cell transplantation.
The CsA-loaded 3D drug carrier has great potential to 
reduce immune rejection when used as a xenogeneic cell 
carrier in vivo. We delivered a human-derived cell source 
(HLF) to a subcutaneous site in a mouse. The CsA-loaded 
3D drug carrier properly regulated mononuclear cell infil-
tration and T-cell-mediated rejection arising from xeno-
geneic cell transplantation. This result implies that the 
Figure 7. Quantification of immune rejection-related cytokines secreted by ConA-activated spleen cells on the CsA-loaded 3D drug 
carriers. ELISAs for the production of (a) IL-2, (b) IL-17, (c) IFN-g (cell only, activated spleen cells; DC, 3D drug carriers without 
CsA; DC-CsA, CsA-loaded 3D drug carriers). **p < 0.005, ***p < 0.001.
Figure 6. In vitro cytokine production versus concentration of CsA. ELISA of the production of (a) IL-2, (b) IL-17, (c) IFN-g by 
ConA-activated spleen cells. *p < 0.05, **p < 0.005, ***p < 0.001.
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Figure 8. Subcutaneous implantation of HLF-seeded 3D drug carriers into BALB/c mouse. (a) Schematic design of HLF seeding 
and subcutaneous implantation of HLF-seeded 3D drug carriers into BALB/c mouse. (b) Visualized mononuclear cell infiltration 
by H&E [C, implanted 3D drug carrier; control, 3D drug carrier without CsA, (+)HLF (−)CsA, HLF seeded 3D drug carrier without 
CsA; (+)HLF (+)CsA, HLF seeded 3D drug carrier with CsA]. (c) The degree of the mononuclear cell infiltration [control, 3D drug 
carrier without CsA; CsA(−), HLF seeded 3D drug carrier without CsA, CsA(+), HLF seeded 3D drug carrier with CsA]. *p < 0.05, 
**p < 0.005, ***p < 0.001.
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immunosuppressive properties of CsA were conserved 
during the fabrication process and the release period, and 
that the locally delivered CsA can act as a calcineurin 
inhibitor to modulate immune rejection responses in vivo 
for up to 4 weeks. Many researchers have been trying to 
find a way to deliver CsA effectively, but most previous 
studies have been limited to systemic or transdermal/
topical delivery; only one study has reported findings 
about local delivery of CsA by polymeric carrier systems 
such as electrospun nanofiber (19). In this respect, our 
developed CsA-loaded drug carrier suggests a possible 
method to obtain local and sustained CsA delivery.
Many reports have considered the limitations of micro-
spheres or hydrogel-based drug delivery systems. In this 
study, several existing problems were overcome by com-
bining microspheres and hydrogel. First, the CsA-Algi gel 
prevents phagocytosis of PLGA microspheres and retains 
microspheres at the injection site. Moreover, the reported 
drug/cell carrier has an advantage over hydrogel-based 
delivery systems due to its structural stability. Generally, 
the physiological conditions bring many problems regard-
ing the breakup of the drug carriers (18). In this study, the 
load-bearing capacity of the developed CsA-loaded 3D 
drug carriers was improved, and the carriers maintained 
their shapes from 1 week to 4 weeks in vivo. 
We have shown that the developed drug delivery sys-
tem can act as CsA delivery carriers adequately. However, 
further investigation must be conducted to assess how the 
actual dose of the drug depends on the concentration of 
cells and to quantify the work efficiency of the delivered 
cells. Additionally, although we evaluated immunosup-
pressive effects over 4 weeks in vivo, the long-term 
effects of DC-CsA should be evaluated over the entire 
period of acute rejection.
This research could be a fundamental study for over-
coming existing limitations, mainly caused by systemic 
immunosuppression. Especially, bio-3D printing tech-
nology should facilitate a wider range of applications, 
such as transplant surgery as well as cell-based therapy. 
For example, the drug carrier could be fabricated with 
the shape of membrane type, which might enable effec-
tive local immunosuppression to a specific area by easily 
sticking to the surgical site. Therefore, various practical 
research studies should also be performed in the future 
to achieve immunosuppression efficacy for actual appli-
cations such as the treatment of intractable diseases that 
require cell-based therapies or a type of transplantation.
CONCLUSION
We developed CsA-loaded 3D drug carriers for trans-
plantation of xenogeneic cells. The developed carrier 
locally suppressed the immune response and therefore did 
not induce a rejection response after xenogeneic cell trans-
plantation. The CsA-Algi gel prevents migration of micro-
spheres; therefore, it cannot provoke an embolism; it can 
also prohibit phagocytosis by macrophages. Moreover, its 
improved load-bearing capacity enables the structure to 
maintain its original shape during the implantation period. 
The developed carrier is a promising solution to treat sev-
eral diseases that require cell-based therapy, such as mus-
cular dystrophy, degenerative disc disease, or myocardial 
infarction, and this system could be used as part of a cell 
therapy product to deliver cells and drugs efficiently to 
desired sites.
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Figure 10. Shape of the implanted 3D drug carriers into BABL/c mouse model after 4 weeks [Control, 3D drug carrier without CsA; 
(+)HLF (−)CsA, HLF seeded 3D drug carrier without CsA; (+)HLF (+)CsA, HLF seeded 3D drug carrier with CsA].
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